Generic Drugs Market, 2012-2023

January 2018 | 182 pages | ID: G213C292892EN
Precision Business Insights (PBI)

Abstracts

Generic Drugs market: A generic drug is pharmaceutical drug, which is bio equivalent to branded drug. Generic drugs are usually approved after patent expiration of patent drugs.

Global Market Outline: Generic Drugs Market

Global generic drugs market is driven by the prevalence of various diseases, need for cost effective drugs for treatment, and government initiatives to increase the use of generic drugs. In addition, favourable regulatory policies, expiry of the branded drugs, and growth in biosimilars segment are expected to boost the generics drugs market. Furthermore, participants in the supply chain such as wholesalers, retailers and pharmacies also benefit from the sale of the generic drugs with high margins compared to branded generics. This emerged as key driver for the growth of global generic drugs market. However, lack of awareness about the availability of generic drugs, competition from branded generics and lack of price control are hampering the generic drugs market.

Generic Drugs market segmented based on therapeutic area and distribution channel

Based on therapeutic area, global generic drugs market is segmented into

• Cardiovascular
• CNS
• Antibiotics
• Oncology
• Gastrointestinal
• Hormones
• Pain Management
• Others

Based on distribution channel, global generic drugs market is segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Generic drugs market is highly fragmented market, presence of large players and small players. To improve their market position in generic drug market companies are adopting strategies like expanding their market presence through collaboration and entering into new markets. For instance, in January 2017, Medical inhaler company Vectura Group PLC collaborated with Sandoz, a division of Novartis AG, to develop a generic version of an inhaler therapy for asthma and COPD (chronic obstructive pulmonary disease). In January 2016, Momenta collaborated with Mylan Laboratories for the development, manufacture and commercialization of six of its biosimilar candidates, including M834, Orencia (abatacept) a biosimilar candidate. Mergers and acquisitions are key strategies adopted by various market players. For instance, in August 2016, Teva Pharmaceutical Industries Ltd Acquired Allergen’s generic business Actavis Generics to expand their product, R&D portfolio and geographical footprint in generic market.

Geographically generic drugs market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America generic drugs market is expected to grow at significant rates owing to availability of more number of generics, increase awareness about the generic drugs and favourable regulatory policies and acts such as Affordable Care Act 2010. In Europe region, Belgium and UK expected to grow at notable rates owing to prevalence of chronic diseases, increase in investment on biosimilars, and increase awareness about generic drugs. Asia Pacific Region expected to be fastest growing due to increased government initiatives in usage of generic drugs and increase in awareness about generic drugs. Especially emerging countries like India government initiating different policies and schemes to boost the usage of generic drugs, For instance, Government of India taken an initiative of opening Jan aushadhi stores to make available quality generic medicines at affordable prices to all citizens.

Some of the market players in generic drugs market are Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Teva Pharmaceutical Industries, Ltd. (Israel), Dr Reddy’s Laboratories (India), Novartis AG (Sandoz International GmbH) (Switzerland), Apotex Holdings Inc. (Canada), Endo International plc (U.S.), Pfizer Inc. (U.S.), Johnson & Johnson Services Inc., (Janssen Pharmaceutica) (U.S.), Lupin Limited (India), Merck & Co, Inc. (U.S.), Mitsubishi Tanabe Pharma (Japan), Momenta Pharmaceuticals (U.S.), Nexus Pharmaceuticals (U.S.), and Novo Nordisk (Denmark) to name a few.

In August 2017, Nexus Pharmaceuticals got U.S. FDA approval for the first generic version of Hospira’s Isuprel, for the treatment of bradycardia, heart block.

In January 2015, Ivax Pharmaceuticals, a subsidiary of Teva Pharmaceuticals has got FDA approval for first generic version of AstraZeneca’s Nexium to treat gastroesophageal reflux disease (GERD).

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL GENERIC DRUGS MARKET INTRODUCTION

2.1. Global Generic Drugs Market – Taxonomy
2.2. Global Generic Drugs Market –Definitions
  2.2.1. Therapeutic Area
  2.2.2. Distribution Channel

3. GLOBAL GENERIC DRUGS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Generic Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Generic Drugs Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Generic Drugs Market – Therapeutic Area Pipeline Analysis

4. GLOBAL GENERIC DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL GENERIC DRUGS MARKET, BY THERAPEUTIC AREA, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Cardiovascular
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. CNS
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Antibiotics
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Oncology
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Gastrointestinal
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Hormones
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis
5.7. Pain Management
  5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.7.3. Market Opportunity Analysis
5.8. Others
  5.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.8.3. Market Opportunity Analysis

6. GLOBAL GENERIC DRUGS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Hospital Pharmacies
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Others
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis

7. GLOBAL GENERIC DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.5.3. Market Opportunity Analysis
7.6. Global Generic Drugs Market - Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Region, 2017 – 2023

8. NORTH AMERICA GENERIC DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Therapeutic Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  8.1.1. Cardiovascular
  8.1.2. CNS
  8.1.3. Antibiotics
  8.1.4. Oncology
  8.1.5. Gastrointestinal
  8.1.6. Hormones
  8.1.7. Pain Management
  8.1.8. Others
8.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  8.2.1. Hospital Pharmacies
  8.2.2. Retail Pharmacies
  8.2.3. Online Pharmacies
  8.2.4. Others
8.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  8.3.1. U.S.
  8.3.2. Canada
8.4. North America Generic Drugs Market - Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2017 – 2023
8.5. North America Generic Drugs Market Dynamics – Trends

9. EUROPE GENERIC DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Therapeutic Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Cardiovascular
  9.1.2. CNS
  9.1.3. Antibiotics
  9.1.4. Oncology
  9.1.5. Gastrointestinal
  9.1.6. Hormones
  9.1.7. Pain Management
  9.1.8. Others
9.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Hospital Pharmacies
  9.2.2. Retail Pharmacies
  9.2.3. Online Pharmacies
  9.2.4. Others
9.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Germany
  9.3.2. UK
  9.3.3. France
  9.3.4. Spain
  9.3.5. Italy
  9.3.6. Russia
  9.3.7. Poland
  9.3.8. Rest of Europe
9.4. Europe Generic Drugs Market - Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2017 – 2023
9.5. Europe Generic Drugs Market Dynamics – Trends

10. ASIA-PACIFIC GENERIC DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Therapeutic Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Cardiovascular
  10.1.2. CNS
  10.1.3. Antibiotics
  10.1.4. Oncology
  10.1.5. Gastrointestinal
  10.1.6. Hormones
  10.1.7. Pain Management
  10.1.8. Others
10.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Hospital Pharmacies
  10.2.2. Retail Pharmacies
  10.2.3. Online Pharmacies
  10.2.4. Others
10.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Japan
  10.3.2. China
  10.3.3. India
  10.3.4. ASEAN
  10.3.5. Australia & New Zealand
  10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Generic Drugs Market - Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2017 – 2023
10.5. Asia-Pacific Generic Drugs Market Dynamics – Trends

11. LATIN AMERICA GENERIC DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Therapeutic Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Cardiovascular
  11.1.2. CNS
  11.1.3. Antibiotics
  11.1.4. Oncology
  11.1.5. Gastrointestinal
  11.1.6. Hormones
  11.1.7. Pain Management
  11.1.8. Others
11.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Hospital Pharmacies
  11.2.2. Retail Pharmacies
  11.2.3. Online Pharmacies
  11.2.4. Others
11.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Brazil
  11.3.2. Mexico
  11.3.3. Argentina
  11.3.4. Venezuela
  11.3.5. Rest of Latin America
11.4. Latin America Generic Drugs Market - Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2017 – 2023
11.5. Latin America Generic Drugs Market Dynamics – Trends

12. MIDDLE EAST AND AFRICA GENERIC DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Therapeutic Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Cardiovascular
  12.1.2. CNS
  12.1.3. Antibiotics
  12.1.4. Oncology
  12.1.5. Gastrointestinal
  12.1.6. Hormones
  12.1.7. Pain Management
  12.1.8. Others
12.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Hospital Pharmacies
  12.2.2. Retail Pharmacies
  12.2.3. Online Pharmacies
  12.2.4. Others
12.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Gulf Cooperation Council (GCC) Countries
  12.3.2. Israel
  12.3.3. South Africa
  12.3.4. Rest of MEA
12.4. MEA Generic Drugs Market - Opportunity Analysis Index, By Therapeutic Area, By Distribution Channel, and Country, 2017 – 2023
12.5. MEA Generic Drugs Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Therapeutic Area & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Mylan N.V. (U.S.)
  13.2.2. Sun Pharmaceutical Industries Limited (India)
  13.2.3. Teva Pharmaceutical Industries, Ltd. (Israel)
  13.2.4. Dr Reddy’s Laboratories (India)
  13.2.5. Novartis AG (Sandoz International GmbH) (Switzerland)
  13.2.6. Apotex Holdings Inc. (Canada)
  13.2.7. Endo International plc (U.S.)
  13.2.8. Pfizer Inc. (U.S.)
  13.2.9. Johnson & Johnson Services Inc., (Janssen Pharmaceutica) (U.S.)
  13.2.10. Lupin Limited (India)
  13.2.11. Merck & Co, Inc. (U.S.)
  13.2.12. Mitsubishi Tanabe Pharma (Japan)
  13.2.13. Momenta Pharmaceuticals (U.S.)
  13.2.14. Nexus Pharmaceuticals (U.S.)
  13.2.15. Novo Nordisk (Denmark)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS